amivantamab
janssen,genmab
['chrysalis,(-chrysalis2),(-chrysalis-2),(-chrysalis 2)', 'commit', 'nsclc', 'thank you', 'sclc']
thank you and thank you to the asco scientific committee #asco22 for selecting us for oral presentation. updated data from the chrysalis study for amivantamab in metex14 skipping nsclc 
Clinical Senior Lecturer in Experimental Cancer Medicine, The University of Manchester and Consultant in Medical Oncology, The Christie NHS Foundation Trust